The Feinstein Institutes for Medical Research has set up the Convalescent Coronavirus Patient Registry, where those eligible and interested in donating blood can register. Participants will then be referred for blood plasma collection at a New York donation site.
The Feinstein Institutes soon will initiate a clinical trial to investigate the potential benefit and safety of donated plasma that contains antibodies that could help fight the new coronavirus. Patients hospitalized with COVID-19 at North Shore University Hospital in Manhasset, N.Y., or Long Island Jewish Medical Center in New York City will be eligible to receive the convalescent plasma as part of the trial.
“We are eager to team up with Mayo Clinic and the network to collaborate on this novel, experimental therapy, and urge those who can donate to our research to please do so. Your participation may help thousands in need,” said Kevin J. Tracey, MD, president, and CEO of the Feinstein Institutes.
More articles on patient safety and outcomes:
5 US coronavirus patients begin treatment using blood from recovered patients
Why UPMC’s care rationing framework is gaining popularity among hospitals
COVID-19 kills 13% of people over age 80, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
